I understand your question. At the moment we have not undertaken to use that model. It's one we'd have to look at in terms of issues of aid effectiveness and putting ownership and decisions in the hands of developing countries to enable them to access the medicines most relevant, affordable, and efficacious to them. So we'd need to look at it from that perspective.
We'd also need to look at the overall objective of the WTO decision, which was to provide greater flexibility for developing countries to access affordable medicines. So I absolutely understand your question. The model is worth looking at, but CIDA would have to give it consideration within the context of those issues.